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The prebiotic inulin modulates 
gut microbiota but does not 
ameliorate atherosclerosis in 
hypercholesterolemic APOE*3-
Leiden.CETP mice
Lisa R. Hoving  1,2, Saeed Katiraei1,2, Amanda Pronk1,2, Marieke Heijink3, Kelly K. D. Vonk1, 
Fatiha Amghar-el Bouazzaoui1, Rosalie Vermeulen1, Lizette Drinkwaard1, Martin Giera  3, 
Vanessa van Harmelen1,2 & Ko Willems van Dijk1,2,4
Gut microbiota have been implicated in the development of atherosclerosis and cardiovascular disease. 
Since the prebiotic inulin is thought to beneficially affect gut microbiota, we aimed to determine the 
effect of inulin supplementation on atherosclerosis development in APOE*3-Leiden.CETP (E3L.CETP) 
mice. Female E3L.CETP mice were fed a western-type diet containing 0.1% or 0.5% cholesterol with 
or without 10% inulin. The effects of inulin were determined on: microbiota composition, cecal short-
chain fatty acid (SCFA) levels, plasma lipid levels, atherosclerosis development, hepatic morphology 
and hepatic inflammation. Inulin with 0.5% dietary cholesterol increased specific bacterial genera 
and elevated levels of cecal SCFAs, but did not affect plasma cholesterol levels or atherosclerosis 
development. Surprisingly, inulin resulted in mild hepatic inflammation as shown by increased 
expression of inflammation markers. However, these effects were not accompanied by increased 
hepatic macrophage number. Analogously, inulin induced mild steatosis and increased hepatocyte 
size, but did not affect hepatic triglyceride content. Inulin with 0.1% dietary cholesterol did not affect 
hepatic morphology, nor hepatic expression of inflammation markers. Overall, inulin did not reduce 
hypercholesterolemia or atherosclerosis development in E3L.CETP mice despite showing clear prebiotic 
activity, but resulted in manifestations of hepatic inflammation when combined with a high percentage 
of dietary cholesterol.
Atherosclerosis is a narrowing of arteries due to accumulation of lipids and cells in the intima, leading to cardio-
vascular diseases (CVD) including heart attack and stroke. CVD are a leading cause of morbidity and mortality 
in Western Society1. Hypercholesterolemia is one of the main underlying risk factors of atherosclerosis develop-
ment, and is routinely treated by prescription of statins. However, statin treatment lowers total plasma cholesterol 
levels by approximately 30%2 and only prevents 25–45% of all cardiovascular events3, indicating the demand for 
additional therapies. The gut microbiota have been discovered as an important player in the onset of atherosclero-
sis and CVD4. Disturbances in lipid metabolism, the precursor for the development of atherosclerosis and CVD, 
have also been associated with gut microbiota dysbiosis in both rodents5 and humans6. A well-known factor 
that modulates the gut microbiota composition and function are dietary fibers or prebiotics. Inulin is a widely 
studied prebiotic that has been shown to beneficially modify gut microbiota composition and function7. Inulin is 
fermented by specific bacteria in the gut, leading to outgrowth of these bacteria and short-chain fatty acid (SCFA) 
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production8, which is thought to improve colonic and systemic health9. Inulin has been shown to exert multiple 
beneficial effects on the host, including lowering inflammation10,11, as well as decreasing hyperlipidemia12–15. 
Whether inulin affects the development of atherosclerosis is currently underexplored. Therefore, we set out to 
determine the effect of inulin on the development of atherosclerosis in hypercholesterolemic APOE*3-Leiden.
CETP (E3L.CETP) mice, a model that is characterized by a human-like lipoprotein metabolism and that is sus-
ceptible to the development of atherosclerosis. Particularly female E3L.CETP mice are highly sensitive to dietary 
cholesterol and they respond in a human-like manner to lipid-lowering anti-atherogenic therapies16. We found 
that inulin drastically altered gut microbiota composition and function. However, inulin neither decreased hyper-
cholesterolemia nor ameliorated atherosclerosis development in this mouse model. Notably, inulin in combina-
tion with a high percentage of dietary cholesterol resulted in manifestations of hepatic inflammation.
Results
Inulin modified gut microbiota composition and function. To determine the effects of inulin on gut 
microbiota in mice fed a WTD with 0.5% cholesterol, 16S rRNA gene sequencing was used to assess the effect 
of inulin on gut microbiota composition and relative abundance of specific gut microbial taxa. Cluster analysis 
based on unweighted UniFrac distances revealed a clear difference between the control group and the inulin 
group after 11 weeks of intervention, while the control group did not change after 11 weeks compared to the 
baseline measurement (Fig. 1A).
Further analysis of the gut microbiota revealed clear differences in the composition of the microbial commu-
nity between the control group and the inulin group. Figure 1B schematically depicts LEfSe’s results included in 
a cladogram showing the significant differences on each taxonomic level with a maximum depth to genus level. 
Table 1 shows the relative abundances (%) of genera in the control and the inulin group and the percentage dif-
ference between the two groups based on LEfSe and ANCOM analyses. Based on LEfSe analysis, inulin signifi-
cantly increased the relative abundance of the genera Coprococcus (+409%), and Allobaculum (+833%), whereas 
the genera Bacteroides (−59%), Parabacteroides (−60%), Prevotella (−88%), Micispirillum (−100%), Clostridium 
(−100%), and Coprobacillus (−100%) were reduced compared to control mice (Table 1). Based on ANCOM 
analysis, inulin increased the relative abundance of the genera Coprococcus (+409%), Ruminococcus (+52%), 
Allobaculum (+833%), and Sutterella (+12%), whereas the genera Mucispirillum (−100%) and Coprobacillus 
(−100%) were decreased compared to control mice (Table 1). The overlapping genera that significantly increased 
after inulin supplementation compared to control mice according to both analyses were Allobaculum and 
Coprococcus.
Subsequently, we determined the effects of inulin on SCFA levels in the cecum. Inulin increased cecal levels 
of propionate (+57% vs. control; P = 0.0005) and butyrate (+146% vs. control; P = 0.0002), but not of acetate 
(Fig. 1C). These data indicate that dietary inulin supplementation modulated both microbial composition and 
function in E3L.CETP mice.
Inulin neither decreased hyperlipidemia nor ameliorated atherosclerosis development. Given 
the potential beneficial effects of inulin on plasma lipid parameters, we determined the effect of inulin on plasma 
triglycerides (TG) and total cholesterol (TC) levels in E3L.CETP mice fed a Western-type diet (WTD) contain-
ing 0.5% cholesterol ± inulin. Surprisingly, inulin did not affect plasma TG levels (Fig. 2A), plasma TC levels 
(Fig. 2B), or TC exposure (Fig. 2C). In order to determine whether inulin affected atherosclerosis development, 
we measured atherosclerosis progression in the aortic root of the heart after 11 weeks of inulin supplementation. 
Representative images (Fig. 2D) illustrate that inulin did not affect mean atherosclerotic lesion area throughout 
the aortic root (Fig. 2E). Finally, there was no effect of inulin on body weight (Fig. 2F) or food intake (Fig. 2G) in 
these mice. These data show that inulin did not beneficially lower plasma lipid levels and did not affect atheroscle-
rosis development in hypercholesterolemic E3L.CETP mice.
Inulin adversely affected the liver by manifestations of hepatic inflammation. Although inulin 
did not affect hyperlipidemia and atherosclerosis, we found that inulin increased liver weight in mice fed a WTD 
containing 0.5% cholesterol (+34% vs. control; P = 0.003; Fig. 3A). We observed notable hepatic morphological 
derangements in the inulin group (Fig. 3B). Inulin significantly increased hepatic hypertrophy as indicated by 
increased hepatocyte size (+20% vs. control; P = 0.008; Fig. 3C). Inulin increased microvesicular steatosis (+37% 
vs. control; P = 0.006) and macrovesicular steatosis (+167% vs. control; P = 0.03)(Fig. 3D), but did not affect 
hepatic TG content (Fig. 3E). Hepatic gene expression of F4/80 (+65% vs. control; P = 0.002), Mcp-1 (+186% vs. 
control; P = 0.0009), Tnf-α (+139% vs. control; P = 0.008), and IL-6 (+67% vs. control; P = 0.04) were higher in 
the inulin group without any effect on IL-10 expression, indicating a pro-inflammatory phenotype in the mice fed 
inulin (Fig. 3F). However, inulin did not lead to changes in the macrophage marker F4/80 as quantified by immu-
nohistochemical staining (Fig. 3G). These data indicate that inulin in combination with 0.5% dietary cholesterol 
adversely affected liver morphology and resulted in manifestations of hepatic inflammation in hypercholester-
olemic E3L.CETP mice.
Inulin in combination with 0.1% dietary cholesterol increased SCFAs in cecum content, but 
did not affect hyperlipidemia or hepatic inflammation. We subsequently determined whether inu-
lin in combination with a more moderate percentage of dietary cholesterol (0.1%) would lead to different out-
comes. Using this lower percentage of dietary cholesterol, hypercholesterolemia is induced to a lower extent 
compared with 0.5% dietary cholesterol. Indeed, 0.5% dietary cholesterol resulted in final plasma TC levels of 
27.6 ± 1.5 mM, while 0.1% dietary cholesterol resulted in plasma TC levels of 15.6 ± 0.3 mM (Fig. 4A). Similar to 
mice fed 0.5% cholesterol, inulin in combination with 0.1% dietary cholesterol significantly elevated levels of pro-
pionate (+188% vs. control; P < 0.0001) and butyrate (+344% vs. control; P < 0.0001) in cecum content (Fig. 4B). 
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However, 0.1% dietary cholesterol with inulin also increased levels of acetate in cecum content (+90% vs. control; 
P < 0.0001; Fig. 4B). Inulin in combination with 0.1% cholesterol did not affect plasma TG levels (Fig. 4C), plasma 
TC levels (Fig. 4D), or liver TG content (Fig. 4E), but increased liver weight (Fig. 4F) which was similar to mice 
fed 0.5% cholesterol. However, in contrast to mice fed inulin with 0.5% cholesterol, inulin combined with 0.1% 
cholesterol did not affect hepatic morphology (Fig. 4G), hepatocyte size (Fig. 4H), microvesicular or macrovesic-
ular steatosis (Fig. 4I), or hepatic gene expression of inflammatory markers (Fig. 4J). Finally, there was neither an 
effect of inulin on body weight (Fig. 4K) nor on food intake (Fig. 4L) in these mice. These results show that inulin 
in combination with 0.1% cholesterol also modulated gut microbiota function, did also not affect hypercholester-







Figure 1. Inulin modified gut microbiota composition and function. The effect of inulin supplementation on 
microbiota composition and function in mice fed a WTD containing 0.5% cholesterol ± inulin. (A) Principal 
coordinates analysis (PCoA) plot of unweighted UniFrac distances metric of 16S rRNA gene sequences at 
baseline (depicted in red) and for the subsequent control group (depicted in blue) and inulin group (depicted 
in green) after 11 weeks (wks) of treatment. To evaluate similarities between bacterial communities, graphs 
1, 2, and 3 were generated using OTU’s based on the unweighted UniFrac distance metrics PC1 and PC2, 
PC1 and PC3, and PC3 and PC2, respectively, and are shown on multiple two-dimensional arrays. (B) The 
cladogram reports the taxa (highlighted by small circles and by shading) showing relative abundance values 
with a maximum depth to genus level (according to LEfSe). Red or green circles/shading represents taxa that are 
significantly higher in relative abundance, while yellow indicates taxa which did not differ in relative abundance 
between the two groups. The taxonomic level is indicated by letter preceding the underscore: o, order; f, family; 
g, genus. The central point in the cladogram represents the taxonomic domain ‘bacteria’ and each ring outward 
represents the next lower taxonomic level (phylum to genus). The darker the shading of the red or green colours, 
the higher the abundance (n = 8–10 mice per group). (C) Finally, the cecal SCFAs acetate, propionate, and 
butyrate were determined (n = 10 mice per group). Values are presented as means ± SEM. *P < 0.05, **P < 0.01, 
***P < 0.001 vs. control.
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Phylum Class Order Family Genus
Control Inulin Inulin/Control
Abundance (%) Abundance (%) % difference





Bacteroides 15.53 ± 1.87 6.33 ± 1.00 −59%*
Porphyromonadaceae
Parabacteroides 8.88 ± 1.60 3.52 ± 0.71 −60%*
Paraprevotellaceae
Prevotella 17.2 ± 6.29 2.1 ± 2.03 −88%
Rikenellaceae
Unidentified 3.28 ± 0.90 0.06 ± 0.02 −98%
S24-7
Unidentified 5.54 ± 0.90 44.88 ± 2.76 710%
Unidentified














Clostridium 1.52 ± 0.70 0 ± 0 −100%*
Lachnospiraceae
Coprococcus 0.38 ± 0.12 1.91 ± 0.45 403%*$
Ruminococcus 1.08 ± 0.36 1.64 ± 0.44 52%$
Ruminococcaceae
Oscillospira 2.08 ± 0.60 0.96 ± 0.21 −54%
Unidentified 1.48 ± 0.85 0.48 ± 0.11 −68%
Unidentified




Allobaculum 1.88 ± 0.55 17.50 ± 2.30 831%*$
Coprobacillus 1.17 ± 0.44 0 ± 0 −100%*$













Unidentified 1.61 ± 0.75 0.32 ± 0.17 −80%
Table 1. Relative abundance and the percentage difference of the inulin group (n = 10) and the control group 
(n = 8) for each genera at 11 weeks of intervention. Data are presented as mean ± standard error of the mean 
(SEM). *P < 0.05 according to LEfSe analysis; $P < 0.05 according to ANCOM analysis.
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Discussion
Our data show that dietary inulin did not reduce atherosclerosis in E3L.CETP mice fed a WTD with 0.5% choles-
terol. This may not have been surprising, since plasma lipid levels were not decreased by inulin supplementation. 
In contrast, inulin in combination with 0.5% cholesterol was associated with manifestations of hepatic inflam-
mation. To further investigate the interaction between dietary cholesterol and inulin on plasma lipid levels and 
inflammation, we analysed the effect of inulin in combination with 0.1% cholesterol. In this experiment, we found 
no clear signs of hepatic inflammation but again no effects of inulin on plasma lipid levels. Thus, inulin appears 
not to have a cholesterol lowering or anti-atherogenic effect in hypercholesterolemic E3L.CETP mice.
Rault-Nania et al.17, found a 35% reduction in atherosclerotic plaque formation in hypercholesterolemic 
APOE-deficient mice. APOE-deficient mice are characterized by severe hypercholesterolemia due to a virtually 
completely blocked LDL-receptor mediated lipoprotein remnant clearance18. In contrast, E3L.CETP mice express 
a dominant variant of human APOE, which results in a moderately disrupted LDL-receptor mediated lipoprotein 
remnant clearance19. E3L.CETP mice are highly responsive to diet-induced hyperlipidemia and atherosclerosis 
development and have been widely used as preclinical model to study the effects and underlying mechanisms 
of various human drugs16. Furthermore, the APOE-deficient mice in the study of Rault-Nania et al. were fed 
a semi-purified diet based on sucrose, whereas the E3L.CETP mice in our study were fed a WTD. Both mouse 
models are based on C57BL/6 genetic background. However, whether the differential effects of inulin on athero-
sclerosis development in APOE-deficient mice versus E3L.CETP mice are mouse model-specific and/or a result 
of differences in dietary composition and/or housing conditions remain to be determined.
Nevertheless, inulin led to elevations of the SCFAs propionate and butyrate on both 0.1% and 0.5% cholesterol 
diets in E3L.CETP mice. Both propionate and butyrate have been suggested to have beneficial effects on choles-
terol metabolism. Propionate is absorbed in the colon and transported via the portal vein to the liver where it 
can inhibit cholesterol synthesis20. Butyrate is mainly used as energy substrate for colonocytes, and studies in rats 
Figure 2. Inulin neither decreased hyperlipidemia nor ameliorated atherosclerosis development. Mice were fed 
a WTD containing 0.5% cholesterol ± inulin for 11 weeks. (A) Plasma TG levels, (B) plasma TC levels, and  
(C) cumulative TC exposure were determined in 4 hour fasted mice. (D) Representative cross-sections of the 
valve area of the aortic root of the heart stained with HPS are shown, and (E) the mean atherosclerotic lesion area 
from the four consecutive cross-sections. Finally, (F) body weight, and (G) food intake were determined. Values 
are presented as means ± SEM (n = 10 mice per group). P < 0.05 was considered as statistically significant.
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have suggested that ingestion of butyrate may lead to reduced hepatic cholesterol synthesis21. Furthermore, Wang 
et al.22, recently have shown that butyrate improves energy metabolism by reducing energy intake and enhancing 
fat oxidation by activating brown adipose tissue in E3L.CETP mice. Despite elevations of both propionate and 
butyrate in our study, no lipid lowering effects of inulin were observed. However, we cannot exclude that prior 
administration of an inulin containing diet may affect the subsequent response to a cholesterol WTD. This further 
implies that the effects of administration of inulin prior to cholesterol WTD feeding on SCFAs and atherosclerosis 
development remains to be further investigated.
Interestingly, inulin in combination with 0.5% dietary cholesterol led to manifestations of hepatic inflam-
mation. This effect seemed to be dependent on the amount of cholesterol in the diet as inulin did not adversely 
affect the liver when combined with 0.1% cholesterol. We found similar detrimental effects of inulin and choles-
terol in an inflammation-driven cuff-induced atherosclerosis model, were inulin in combination with 1% dietary 
cholesterol even resulted in increased plasma cholesterol levels and aggravated atherosclerosis development23. 
We are not the first ones to show adverse effects of dietary fiber on liver inflammation mediated via gut micro-
biota interactions. In a previous study by Janssen et al.24, specific modulation of the gut microbiota, by feeding 
mice the prebiotic indigestible carbohydrate guar gum, promoted liver inflammation and led to worsening of 
non-alcoholic fatty liver disease (NAFLD) in mice. In this study, the effects of guar gum on liver inflammation 
could be linked to altered circulating and hepatic levels of bile acids. Whether inulin in our study adversely 
affected the liver via changes in bile acid metabolism remains to be investigated.
Inulin has been shown to induce inflammation in previous studies, although in these studies inulin mainly 
exacerbated pre-existing inflammation. For instance Miles et al.25, reported that diets enriched with inulin further 
exacerbated the severity of dextran sulfate sodium (DSS)-induced colitis in mice. It is possible that in our study 
the high-cholesterol diet induced borderline liver inflammation which was exacerbated by inulin.
Inulin is well established to exert bifidogenic effects and the increased abundance of Bifidobacteria in the gut 
microbiota presumably explains the beneficial effects of inulin on health26. Notably, inulin in combination with 
0.5% dietary cholesterol led to major shifts in microbial composition but there was no significant increase in 
the relative abundance of Bifidobacteria. Instead, according to both LEfSe and ANCOM analysis, inulin stimu-
lated the relative abundance of the genera Allobacullum and Coprococcus. Catry et al.27 have previously reported 
that dietary intervention with inulin-type fructans (ITF) improved endothelial dysfunction in which they found 
increased abundance of Allobaculum in APOE−/− mice. Furthermore, Lee et al.28, have reported that feeding 
Figure 3. Inulin adversely affected the liver by manifestations of hepatic inflammation Mice were fed a WTD 
containing 0.5% cholesterol ± inulin for 11 weeks. (A) Liver weight, (B) liver morphology, (C) hepatocyte size 
as a marker for hepatic hypertrophy, (D) microvesicular and macrovesicular steatosis, (E) liver TG content, 
(F) qRT-PCR analysis of F4/80, Mcp-1, Tnf-α, IL-6, IL-10, and (G) immunohistochemical analysis of hepatic 
F4/80 were determined. Values are presented as means ± SEM (n = 10 mice per group). *P < 0.05, **P < 0.01, 
***P < 0.001 vs. control.
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rats a diet rich in cholesterol specifically increased the abundance of Allobaculum and Coprococcus compared 
to a control AIN76A diet. Whether the relative increase in Allobaculum in these and our studies was due to 
inulin supplementation, hypercholesterolemia, or both is not clear. In the study of Lee et al.28, it was found that 
Allobaculum exhibited a negative correlation with anti-inflammatory genes in the gut, indicating that Allobaculum 
plays a role in inflammation. We found a relative decrease in the abundance of Bacteroides, Parabacteroides, 
Prevotella, Mucispirillum, Clostridium, and Coprobacillus after inulin supplementation. Whether the absence of 
Bifidobacteria, relative increase of Allobaculum and Coprococcus, and/or the decrease in relative abundance of 
certain other genera played a role in the underlying mechanism of the manifestations of liver inflammation after 
inulin supplementation on a high cholesterol diet, remains to be investigated.
In conclusion, in this study inulin did neither affect hypercholesterolemia nor atherosclerosis development 
in hypercholesterolemic E3L.CETP mice, but rather resulted in manifestations of hepatic inflammation when 
combined with high percentages of dietary cholesterol. Although inulin is widely acknowledged as a prebiotic 
with favorable effects on lipid metabolism and CVD, inulin clearly not always exerts beneficial effects. It will be 
important for future research to decipher potential adverse pathways and mechanisms that are induced by the 
interaction of inulin with high dietary cholesterol and the gut microbiota. Although the gut microbiota of mice 
differ significantly from humans, E3L.CETP mice respond similarly as patients to a variety of anti-atherosclerotic 
interventions23. Therefore, we interpret our data to indicate caution with the application of inulin to reduce lipid 
levels in humans.
Methods
Mice and diet. In two experiments, female E3L.CETP mice were fed a WTD containing 0.1% or 0.5% cho-
lesterol (Diet T 0.1 (Diet T 4022.16) or Diet T 0.5 (Diet T 4022.17); AB Diets, The Netherlands) (Table 2). This 
WTD diet was supplemented with or without 10% inulin (FrutaFit HD, Sensus, The Netherlands) for a total 
period of 11 weeks in which 10% of cellulose was replaced with 10% inulin. At baseline, after a run-in of 3 weeks 
with WTDs, randomization of the mice was performed based on plasma TC levels, plasma TG levels, and body 
weight. During the intervention period, body weight and food intake were measured weekly. After 11 weeks, 
Figure 4. Inulin in combination with 0.1% dietary cholesterol increased SCFAs in cecum content, but did not 
affect hyperlipidemia or hepatic inflammation. Mice were fed a WTD containing 0.1% cholesterol ± inulin 
for 11 weeks (n = 17 mice per group). (A) Plasma TC levels for control and inulin fed mice on both 0.5% 
dietary cholesterol (n = 10 mice per group) and 0.1% dietary cholesterol for 0, 4, 8, and 10 weeks of dietary 
intervention. (B) The cecal SCFAs acetate, propionate, and butyrate, (C) plasma TG levels, (D) plasma TC 
levels, (E) liver TG content, (F) liver weight, (G) liver morphology, (H) hepatocyte size, (I) microvesicular and 
macrovesicular steatosis, (J) qRT-PCR analysis of F4/80, Mcp-1, Tnf-α, IL-6, and IL-10, (K) body weight, and 
(L) food intake were determined. Values are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 
***P < 0.0001 vs. control. ND = non-detectable.
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non-fasted mice were sacrificed using CO2 inhalation. Orbital bleeding was performed to collect blood and mice 
were subsequently perfused with ice-cold PBS through the heart. Cecum content, heart, and liver were collected 
for further analysis. Mice were housed under temperature- and humidity-controlled conditions with a 12:12 h 
light-dark cycle and free access to food and water. A schematic of the experimental study protocol is provided in 
Fig. 5. Mouse experiments were performed in compliance with Dutch government guidelines and the Directive 
2010/63/EU of the European Parliament and had received approval from the University Ethical Review Board 
(Leiden University Medical Center, The Netherlands).
16S rRNA gene sequencing and profiling. 16S rRNA sequencing in cecum samples of E3L.CETP mice 
fed with a WTD (0.5% cholesterol) ± inulin was performed as described previously29. Relative bacterial abun-
dance was determined. For statistical significance, biological relevance and visualisation linear discriminant 
analysis (LDA) effect size (LEfSe) method (https://bitbucket.org/biobakery/biobakery/wiki/lefse)30 and ANCOM 
analysis were used as described previously (https://www.niehs.nih.gov/research/resources/software/biostatistics/
ancom/index.cfm)31. Prior to LEfse analysis low abundant taxa were filtered out, applying a two-step filtering. 
First, taxa that were present in less than half of the group size were filtered out. In a second step, very rare taxa that 
were abundant less than 0.5% of total group taxa were filtered out. At baseline and after 11 weeks (wks) of inter-
vention, jack-knifed β-diversity of unweighted UniFrac distances, with 10 jack-knifed replicates was measured at 
rarefaction depth of 22000 reads per sample, based on the unfiltered OTU table.
Cecal short-chain fatty acid analysis. Cecum SCFA content was analysed using gas chromatography 
mass spectrometry (GC-MS) as described previously32.
Plasma parameters. Plasma TG and TC were measured in 4 hour fasted mice as described previously29. 
Plasma cholesterol exposure was calculated as the cumulative exposure over the number of weeks where mice 
were fed a WTD ± inulin.
Dietary substitute (%) Control/Inulin 0.1% Control/Inulin 0.5%
Inulin 0/10 0/10
Cholesterol 0.1 0.5
Magnesium oxide 0.2 0.2
Methionine 0.2 0.2
Standard trace elements premix 0.25 0.25
Standard vitamin premix 0.25 0.25
Salt 0.3 0.3
Magnesium sulphate heptahydate 0.4 0.4
Potassium hydrogen phosphate 0.7 0.7
Potassium chloride 0.7 0.7
Calcium carbonate 1 1
Corn oil 1 1
Calcium hydrogen phosphate 1.3 1.3
Choline chloride 2 2
Corn starch 10 10
Cacoa butter 15 15
Cellulose 16.1/6.1 16/6
Sour casein 20 20
Sugar/sucrose 30.5 30.2
Total 100 100
Table 2. Diet composition (% of total weight).







Figure 5. Experimental study protocol. Experiments were performed independently.
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Atherosclerosis quantification. Atherosclerosis quantification using histological staining with 
hematoxylin-phloxyin-saffron (HPS) was performed in hearts of E3L.CETP mice fed a WTD (0.5% choles-
terol) ± inulin as described previously29. Image J Software (NIH, USA) was used for the quantification of ather-
osclerotic lesion areas.
Liver (immuno)histochemistry. Livers were removed, fixed in 4% paraformaldehyde, dehydrated in 
70% ethanol, embedded in paraffin and sectioned (5 µm). Paraffin-embedded liver sections were stained with 
haematoxylin and eosin (H&E) using standard protocols. From H&E-stained sections, hepatocyte size (hepatic 
hypertrophy) was quantified as the average number of hepatocytes per total microscopic field (mm2) per section. 
H&E-stained liver sections were scored for hepatic steatosis on the level of microvesicular and macrovesicular 
steatosis33, expressed as the percentage of the total liver section area affected. Immunohistochemical detection 
of the macrophage marker F4/80 was done on paraffin-embedded sections that were treated with proteinase K, 
using a primary Rat Anti-Mouse F4/80 monoclonal Ab (MCA497; 1:600, Serotec, UK) and a secondary Goat 
Anti-Rat immunoglobulin peroxidase (MP-7444, Vector Laboratories Inc., USA). All histological and histochem-
ical analysis were analysed using Image J software (NIH, USA).
Liver lipids. Lipids were extracted from the liver according to a protocol from Bligh and Dyer34 and modified 
as described previously29. TG content was assayed as described above.
RNA isolation and qRT-PCR. Snap-frozen liver samples were used for the extraction of RNA using 
a NucleoSpin RNA kit (Machery-Nagel, Germany). NanoDrop ND-1000 spectrophotometer (Isogen, The 
Netherlands) was used to determine concentrations and purity of RNA. Reverse transcription of RNA was done 
using Moloney Murine Leukemia Virus Reverse Transcriptase (Promega, The Netherlands). Gene expression lev-
els were determined using qRT-PCR, SYBR green supermix (Biorad, The Netherlands), and gene-specific primers 
(Table 3). Expression of mRNA was normalized to cyclophilin (CypA) and ribosomal protein large P0 (Rplp0) 
RNA, and expressed as fold change versus control using the ΔΔ CT method.
Statistical analysis. Data are presented as means ± SEM. Normal distribution of the data was tested using 
D’Agostino-Pearson omnibus normality test, and data were analysed with the unpaired Student’s t-test in case of 
normal distribution or with the nonparametric Mann–Whitney U test in case of not normally distributed data. 
Differences in body weight over time were evaluated for statistical significance by two-way ANOVA followed by 
Sidak’s post hoc multiple comparison test. P < 0.05 was considered as statistically significant. Analyses were per-
formed using Graph Pad Prism version 7.0 (GraphPad Software, USA).
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